SBIO

Fund Description
The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
Fund Profile
Fund Name ALPS Medical Breakthroughs ETF
Fund Exchange Ticker SBIO
Fund Sponsor ALPS
Fund ISIN US00162Q5936
Net Expense Ratio 0.50 %
Fund Inception Date 31 December 2014
Fund Legal Structure ETF (Open end fund)
Exchange NYSE Arca
Listing Country Code US
Fund Investment Objective
ETF Type Specific US Equities - Industry Sector
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Poliwogg Medical Breakthroughs Index
Index Provider Poliwogg Index
Currency Hedged No
Inverse / Leveraged Not Applicable
Developed / Emerging Developed Market Funds
Market Capitalization Range SMID (Small & Mid) Cap
Growth Value Core / Blend
Continent North America
Key Statistics
Return As of Date 17 January 2019
Asset Under Management 185.36 Million (USD)
1 Month Total Return 10.37 %
Year To Date Return 15.57 %
1 Year Total Return -1.88 %
3 Year Annualized Total Return 10.57 %
NAV 32.52
Share Outstanding 5,700,000
Top 10 Holdings (17 January 2019)
Constituent Name Constituent Ticker Constituent Type Weighting
LOXO ONCOLOGY INC LOXO EQUI 0.0703000000
FIBROGEN INC FGEN EQUI 0.0527000000
ARRAY BIOPHARMA INC ARRY EQUI 0.0454000000
UNITED THERAPEUTICS CORP UTHR EQUI 0.0443000000
GALAPAGOS NV GLPGF EQUI 0.0427000000
IMMUNOMEDICS INC IMMU EQUI 0.0404000000
AGIOS PHARMACEUTICALS INC AGIO EQUI 0.0399000000
EMERGENT BIOSOLUTIONS INC EBS EQUI 0.0390000000
ASCENDIS PHARMA A/S - ADR ASND EQUI 0.0377000000
GLOBAL BLOOD THERAPEUTICS IN GBT EQUI 0.0325000000